Mesoblast Limited (NASDAQ:MESO) has been assigned an average recommendation of “Hold” from the nine brokerages that are covering the firm, Marketbeat.com reports. Three analysts have rated the stock with a sell recommendation, two have issued a hold recommendation and four have issued a buy recommendation on the company. The average 1-year price target among brokers that have updated their coverage on the stock in the last year is $14.25.
MESO has been the topic of a number of recent analyst reports. Maxim Group set a $14.00 target price on Mesoblast and gave the company a “buy” rating in a research report on Wednesday, November 15th. Zacks Investment Research lowered Mesoblast from a “buy” rating to a “hold” rating in a research report on Wednesday, November 1st. Oppenheimer set a $16.00 price target on Mesoblast and gave the company a “buy” rating in a research report on Tuesday, November 14th. Finally, ValuEngine lowered Mesoblast from a “hold” rating to a “sell” rating in a research report on Friday, September 15th.
Mesoblast (NASDAQ MESO) opened at $5.64 on Wednesday. Mesoblast has a 52-week low of $4.80 and a 52-week high of $12.50. The stock has a market capitalization of $522.57, a P/E ratio of -6.88 and a beta of 2.44.
Receive News & Ratings for Mesoblast Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mesoblast and related companies with MarketBeat.com's FREE daily email newsletter.